Duloxetine in Inflammatory Bowel Diseases

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT07431606
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Inflammatory Bowel Diseases

Eligibility Criteria

Sex
ALL
Age
24 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Duloxetine — DRUG
    antidepressant; central neuromodulator

Study Details

This open-label, prospective, single-arm pilot study investigates the use of duloxetine, a central neuromodulator, for improving psychological distress and functional impairment in adults with inflammatory bowel disease (IBD). The study focuses on patient-reported outcomes related to anxiety, depression, and IBD-related disability, aiming to assess feasibility, tolerability, and preliminary efficacy in modulating gut-brain axis symptoms and disease-related functional impairments in life

Key Dates

First listed
Feb 24, 2026
Start date
May 1, 2026
Status verified
Feb 2026
Primary completion
Mar 1, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Duloxetine
    Duloxetine 30-60 mg daily per oral

Primary Outcome Measure

Change in IBD-related disability [ Time Frame: 6 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of PennsylvaniaPhiladelphiaPennsylvania19104
Chung Tse, MD
[email protected]
2153498222
Maureen DeMarshall, RN
[email protected]
2153498546

Find similar trials in Philadelphia, PA

By research site
University of Pennsylvania· Philadelphia, PA

Related Studies